Gelteq Ltd (NASDAQ: GELS)

Gelteq Ltd is a clinical and science‑based company that develops and commercializes white label gel‑based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm produces edible gels that serve as dosage forms, focusing on five verticals—pets, sports, pharmaceutical, over‑the‑counter and nutraceutical—using patent‑pending multi‑ingredient formulations. Gelteq’s business model centers on out‑licensing its technology to partners who rebrand the gels, while it also manufactures existing products under its own white label arrangement.

Revenue is generated primarily through licensing agreements and the manufacture of white label gel products for third‑party clients. The company receives upfront payments, milestone fees and revenue upon delivery of ordered units, as evidenced by historic shipments to sports teams and nutraceutical firms. Royalties or fees may also arise from ongoing sales of licensed products, contributing to top‑line growth as order volumes increase.

The company operates through the following segments:

• Pet gels: This segment develops gel‑based supplements for companion animals, targeting joint health, coat quality, immune support, weight loss, diabetes and digestion for felines and canines. Formulations are laboratory‑tested, flavored and shelf‑stable, ready for scale‑up production with third‑party manufacturers.

• Pharmaceutical/OTC gels: This segment creates gel dosage forms for prescription and over‑the‑counter drugs, with a focus on pain management and other therapeutics. Activities include pursuing FDA approval via the 505(b)(2) pathway, conducting dissolution and bioequivalence studies, and adapting the gel platform for veterinary drugs that have received suitability petitions.

• Nutraceuticals/sports nutrition gels: This segment supplies gel products for human nutrition and sports performance, incorporating electrolytes, carbohydrates, vitamins, probiotics and other active ingredients. It has delivered products to sports clubs and nutraceutical companies, and continues to develop new formulations for brain function and general wellness.

Gelteq occupies a niche in the drug delivery industry where its gel technology offers taste‑masking, ease of swallowing and flexible release characteristics that differentiate it from traditional pills, capsules and liquids. While competitors such as Oramed Pharmaceuticals, IntelGenx Technologies, BioDelivery Sciences International, Lexaria Bioscience, Taro Pharmaceuticals, Catalent, Insulet, Nutriband, Virpax Pharmaceuticals and Hempfusion explore alternative delivery systems, Gelteq notes that no other firm currently provides a comparable gel‑based platform for multi‑ingredient dosing, giving it a first‑mover advantage in several verticals.

The company’s customer base includes sports teams such as PacificPine Tennis Limited, PacificPine Football Limited, PacificPine Golf Limited and Five‑Star Sports Hong Kong Limited, nutraceutical partners like Healthy Extracts Inc. and Lifestyle Breakthrough Holdings Pty Ltd, and distribution allies such as WPIC Marketing and Technologies Limited for the Asia‑Pacific region. These customers span the sports, nutraceutical and pet health sectors, ordering gel products for rebranding and sale under their own labels.